Cited 0 times in
Chemoradiotherapy versus surgery followed by postoperative radiotherapy in tonsil cancer: Korean Radiation Oncology Group (KROG) study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Song, S | - |
dc.contributor.author | Wu, HG | - |
dc.contributor.author | Lee, CG | - |
dc.contributor.author | Keum, KC | - |
dc.contributor.author | Kim, MS | - |
dc.contributor.author | Ahn, YC | - |
dc.contributor.author | Oh, D | - |
dc.contributor.author | Park, HJ | - |
dc.contributor.author | Lee, SW | - |
dc.contributor.author | Park, G | - |
dc.contributor.author | Moon, SH | - |
dc.contributor.author | Cho, KH | - |
dc.contributor.author | Kim, YS | - |
dc.contributor.author | Won, Y | - |
dc.contributor.author | Oh, YT | - |
dc.contributor.author | Kim, WT | - |
dc.contributor.author | Jeong, JU | - |
dc.date.accessioned | 2018-08-24T01:49:35Z | - |
dc.date.available | 2018-08-24T01:49:35Z | - |
dc.date.issued | 2017 | - |
dc.identifier.uri | http://repository.ajou.ac.kr/handle/201003/16033 | - |
dc.description.abstract | BACKGROUND: Treatment of tonsil cancer, a subset of oropahryngeal cancer, varies between surgery and radiotherapy. Well-designed studies in tonsil cancer have been rare and it is still controversial which treatment is optimal. This study aimed to assess the outcome and failure patterns in tonsil cancer patients treated with either approaches.
METHODS: We retrospectively reviewed medical records of 586 patients with tonsil cancer, treated between 1998 and 2010 at 16 hospitals in Korea. Two hundred and one patients received radiotherapy and chemotherapy (CRT), while 385 patients received surgery followed by radiotherapy and/or chemotherapy (SRT). Compared with the SRT group, patients receiving CRT were older, with more advanced T stage and received higher radiotherapy dose given by intensity modulation techniques. Overall survival (OS), disease-free survival (DFS), locoregional recurrence-free survival (LRRFS), distant metastasis-free survival (DMFS), and clinicopathologic factors were analyzed. RESULTS: At follow-up, the 5-year OS, DFS, LRRFS and DMFS rates in the CRT group were 82, 78, 89, and 94%, respectively, and in the SRT group were 81, 73, 87, and 89%, respectively. Old age, current smoking, poor performance status, advanced T stage, nodal involvement, and induction chemotherapy were associated with poor OS. Induction chemotherapy had a negative prognostic impact on OS in both treatment groups (p = 0.001 and p = 0.033 in the CRT and SRT groups, respectively). CONCLUSIONS: In our multicenter, retrospective study of tonsil cancer patients, the combined use of radiotherapy and chemotherapy resulted in comparable oncologic outcome to surgery followed by postoperative radiotherapy, despite higher-risk patients having been treated with the definitive radiotherapy. Induction chemotherapy approaches combined with either surgery or definitive radiotherapy were associated with unfavorable outcomes. | - |
dc.language.iso | en | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Chemoradiotherapy | - |
dc.subject.MESH | Chemotherapy, Adjuvant | - |
dc.subject.MESH | Combined Modality Therapy | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Radiotherapy, Adjuvant | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Survival Rate | - |
dc.subject.MESH | Tonsillar Neoplasms | - |
dc.title | Chemoradiotherapy versus surgery followed by postoperative radiotherapy in tonsil cancer: Korean Radiation Oncology Group (KROG) study | - |
dc.type | Article | - |
dc.identifier.pmid | 28854890 | - |
dc.identifier.url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5577763/ | - |
dc.contributor.affiliatedAuthor | 오, 영택 | - |
dc.type.local | Journal Papers | - |
dc.identifier.doi | 10.1186/s12885-017-3571-3 | - |
dc.citation.title | BMC cancer | - |
dc.citation.volume | 17 | - |
dc.citation.number | 1 | - |
dc.citation.date | 2017 | - |
dc.citation.startPage | 598 | - |
dc.citation.endPage | 598 | - |
dc.identifier.bibliographicCitation | BMC cancer, 17(1). : 598-598, 2017 | - |
dc.identifier.eissn | 1471-2407 | - |
dc.relation.journalid | J014712407 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.